RxDoctor Payments DataLook up a doctor →

Casey Stahlheber, MD

Pulmonary Disease · Saint Louis, MONPI 1497950265

Payments from drug & device makers

$27,437in general payments, 2019–2025

Across 1,176 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • GSK$3K
  • AstraZeneca$3K
  • Boehringer Ingelheim$2K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $9K from 50 others

What the payments were for

  • Travel & lodging$7963%
  • Food & beverage$20,52975%
  • Education$6,11122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,437 in reported general payments places this provider in the 80th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$170,389
Medicare patients
613
Services billed
1,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter298$247,349
XolairOmalizumab26$95,783
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr150$91,674
Breo ElliptaFluticasone/Vilanterol126$56,543
Breztri AerosphereBudesonide/Glycopyr/Formoterol62$48,563
Pirfenidone11$47,498
Spiriva RespimatTiotropium Bromide57$41,900
Stiolto RespimatTiotropium Br/Olodaterol Hcl55$29,835
SymbicortBudesonide/Formoterol Fumarate92$29,158
Albuterol Sulfate HfaAlbuterol Sulfate349$8,450
Combivent RespimatIpratropium/Albuterol Sulfate15$8,396
DuleraMometasone/Formoterol15$6,867
Incruse ElliptaUmeclidinium Bromide20$6,570
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14$5,329
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$4,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$3,477$402,136594 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$3,425$83,050168 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$2,282$80,132127 claims
MerckDulera$449$6,86715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →